Atopic Dermatitis

The study suggests that treatments for allergic reactions could help decrease the risk of having joint problems.

Researchers say itch and inflammation markers were not met, and trial results are not conclusive.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.

Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.

Dermatology experts review the design of the TRuE-AD1 and TRuE AD2 phase 3 trial.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, provide an overview of atopic dermatitis and review the burden of disease.

In a clinical study conducted in Japan, researchers found the treatment well-tolerated and efficacious in moderate-to-severe cases.

Silverberg discusses how certain irritants and living situations may cause flares in patients with atopic dermatitis.

Late-breaking positive phase 2a results were presented at AAD 2023.

Although the ingredient is widely used in skincare, the American Contact Dermatitis Society (ACDS) wants clinicians to take special considerations when patch testing for lanolin contact allergy.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

The study also found lasting benefits of the supplement for bone density up to age 4.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

Results from the phase 3 study were presented at an AAD late-breaking research session.

This question drummed up discussion during one AAD 2023 session on the topic. We want to hear from you!

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.

Atopic Dermatitis treatment and management options are explored at several sessions conducted by Peter Lio, MD, FAAD, at AAD 2023.

The latest phase 3 trial results were showcased in an AAD late-breaking research session.

Can dietary modifications really improve dermatological conditions?

Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.

Treatment safety and efficacy for atopic dermatitis has seen significant growth over the last decade.